Viking Therapeutics Reports Another Quarter of Spending Other People's Money on Promise

Viking Therapeutics reports first-quarter 2026 earnings tomorrow after the close, with analysts expecting a loss of $0.95 per share—more than double the $0.41 loss posted in the same quarter last year. The biotech's recent track record of significant earnings misses, combined with heightened volatility around its obesity drug pipeline, makes this release a critical test of investor confidence. With the stock trading below most key moving averages and options pricing an 8.90% expected move, the market is bracing for another volatile reaction.

Part 1: Earnings Preview

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with particular emphasis on its obesity and NASH (non-alcoholic steatohepatitis) drug candidates. The company's lead asset, VK2735, is an oral GLP-1 receptor agonist competing in the rapidly expanding obesity treatment market.

Viking Therapeutics will report Q1 2026 results tomorrow, April 29, after market close. Analysts expect a loss of $0.95 per share on no revenue, representing a 131.71% increase in losses compared to the $0.41 loss reported in Q1 2025. The most recent quarter (Q4 2025) saw the company post a loss of $1.38 per share, significantly worse than the $0.89 consensus estimate.

Three key themes define this earnings story:

Clinical Trial Progress and Timeline Updates: Investors will scrutinize any updates on VK2735's Phase 2 obesity trial results and the timeline for advancing into Phase 3 studies. The competitive landscape in obesity drugs has intensified, with Eli Lilly and Novo Nordisk dominating the market, making Viking's differentiation strategy and clinical data quality critical to maintaining investor enthusiasm.

Cash Runway and Financing Needs: With no revenue and accelerating losses—Q4's $1.38 loss per share was the highest in recent history—the company's cash position and burn rate will be under close examination. Analysts will want clarity on whether Viking has sufficient capital to fund its clinical programs through key milestones or if dilutive financing is on the horizon.

Partnership and Commercialization Strategy: As Viking advances its pipeline, investors are increasingly focused on whether the company will pursue partnerships for development and commercialization or attempt to go it alone. Any commentary on strategic discussions or business development activity could significantly impact the stock's valuation multiple.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. While the 16 Strong Buy ratings and $93.73 average price target (189% upside from current levels) demonstrate long-term conviction in the pipeline, the recent downgrade in Barchart's technical signal from 56% Buy to 0% Hold suggests near-term momentum has stalled as investors await concrete clinical and financial updates.

Part 2: Historical Earnings Performance

Viking Therapeutics has established a consistent pattern of missing earnings estimates across all four of the most recent quarters, with surprises ranging from -15.71% to -55.06%. The trend has worsened significantly over time: Q1 2025 saw a relatively modest 20.59% miss, but by Q4 2025, the company posted a loss of $1.38 per share against expectations of $0.89—a 55.06% miss that marked the worst performance in the recent series.

The magnitude of losses has also accelerated dramatically. Reported EPS deteriorated from $0.41 in Q1 2025 to $1.38 in Q4 2025, more than tripling in just three quarters. This pattern suggests either increasingly aggressive R&D spending as clinical programs advance, or that the company's burn rate is exceeding analyst expectations as it scales operations. Each successive quarter has seen both higher absolute losses and wider misses relative to consensus, indicating analysts have struggled to accurately model the company's cash consumption.

The consistency of these misses—five consecutive quarters according to web sources—raises questions about whether current estimates adequately reflect Viking's spending trajectory. With Q1 2026 estimates calling for a $0.95 loss (more than double the prior-year quarter), investors should be prepared for the possibility of another significant miss if the pattern holds.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Viking Therapeutics reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around Viking's earnings releases shows extreme volatility, with an average absolute Day +1 move of 9.63% and Day +1 range of 13.54%—among the highest in the biotech sector. The most dramatic reactions occurred in mid-2024: the July 2024 report triggered a 28.31% surge on Day +1, while October 2024 saw a 21.25% jump, both following initial Day 0 declines. These explosive moves likely reflected positive clinical trial updates or pipeline developments that overshadowed the earnings misses.

More recently, volatility has moderated but remains elevated. The February 2026 report (most recent) saw a 6.80% Day +1 gain following a modest 0.70% Day 0 decline, while October 2025 produced a 7.96% Day +1 rally after a 4.73% Day 0 drop. This pattern of Day 0 weakness followed by Day +1 strength suggests the market often reacts negatively to the initial headline numbers but then reassesses based on management commentary, pipeline updates, or forward guidance.

The 2.40% average Day 0 move and 5.31% Day 0 range indicate significant anticipatory volatility, while the much larger 9.63% Day +1 average confirms that the real price discovery happens after investors digest the full earnings package. Given Viking's clinical-stage status, these moves are likely driven more by pipeline updates and cash runway commentary than by the actual EPS figures.

Part 2.2: Options Market Expected Move

The options market is pricing a 8.90% expected move for this week's expiration, slightly below the 9.63% average Day +1 move observed historically but well within the typical range. This suggests options traders are anticipating meaningful volatility but not the extreme 20%+ swings seen during major clinical data releases in 2024.

Part 3: What Analysts Are Saying

Analysts maintain overwhelmingly bullish sentiment on Viking Therapeutics, with 16 Strong Buy ratings, 0 Moderate Buys, 3 Holds, and no Sell ratings among the 19 analysts covering the stock. The consensus translates to an average recommendation of 4.68 out of 5.0, reflecting strong conviction in the company's long-term potential despite near-term execution risks.

The $93.73 average price target implies 189% upside from the current $32.39 price, with a wide range spanning from a low of $35.00 to a high of $125.00. This broad dispersion reflects significant uncertainty around the company's clinical trial outcomes, partnership prospects, and ultimate commercial potential in the competitive obesity market. The high-end target of $125.00 likely assumes successful Phase 3 trials and either a lucrative partnership or standalone commercialization success, while the $35.00 low target suggests more conservative assumptions around clinical risk and capital requirements.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 15 to 16 while the average recommendation ticked up from 4.67 to 4.68. This modest strengthening suggests analysts remain confident in the pipeline despite the stock's recent technical weakness and pattern of earnings misses. The lack of any Sell ratings is particularly notable given the company's consistent failure to meet earnings expectations—analysts appear willing to look through near-term losses and focus on the binary clinical and commercial outcomes that will ultimately determine Viking's value.

Part 4: Technical Picture

The Barchart Technical Opinion has deteriorated sharply heading into earnings, shifting from a 56% Buy signal last week to a 0% Hold currently, with last month's reading at 8% Buy. This rapid weakening reflects growing technical pressure as the stock has failed to hold key support levels.

Timeframe Analysis:

• Short-term (50% Buy): Modest buy signal suggests near-term momentum has stalled but hasn't fully reversed, indicating indecision among traders ahead of the earnings release
• Medium-term (Hold): Neutral reading points to consolidation in the intermediate timeframe as the stock digests recent volatility and awaits a catalyst
• Long-term (50% Sell): Moderate sell signal reflects deteriorating longer-term trend structure, with the stock struggling to maintain upward momentum over extended periods

Trend Characteristics: The Bearish directional bias indicates the overall trend environment is working against the stock heading into earnings, suggesting technical traders may be positioned defensively or on the sidelines.

The stock is trading at $32.39, positioned below all six key moving averages: the 5-day ($33.03), 10-day ($34.07), 20-day ($34.10), 50-day ($33.52), 100-day ($33.38), and 200-day ($32.77). This universal underperformance across all timeframes confirms the bearish technical setup, with the stock finding only marginal support at the 200-day moving average. The tight clustering of the 5-day through 100-day averages in the $33-$34 range creates a significant overhead resistance zone that could cap any post-earnings rally. With momentum indicators pointing lower and the stock trading at the bottom of its recent range, the technical picture heading into earnings is cautionary—any disappointment could trigger a break below the 200-day average and accelerate selling pressure, while a positive surprise would need to clear the $33-$34 resistance cluster to signal a meaningful reversal.